Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2011-05-25 Director's Dealing
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Director's Dealing 2011
Director's Dealing Classification · 100% confidence The document text explicitly mentions reporting transactions in accordance with the Danish Securities Trading Act, referencing a specific ISIN and stock symbol (NZYMB). This strongly indicates a report of personal share transactions by executives or directors, which aligns with the definition of Director's Dealing (DIRS). Although the text is very short and suggests reading the 'whole announcement,' the content itself is about reporting specific transactions, making DIRS a more precise fit than the general RPA or RNS fallback.
2011-05-25 English
Director's Dealing 2011
Director's Dealing Classification · 99% confidence The document explicitly reports transactions made by an executive ('Peder Holk Nielsen', EVP) in the company's shares on a specific trading date ('24/5/2011'). It details the volume and value of the sale. This directly aligns with the definition of Director's Dealing (insider trades by executives/directors). The filing category code for this is DIRS.
2011-05-25 English
Share Issue/Capital Change 2011
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that Novozymes initiated a 'share buyback program' for an amount up to DKK 400 million. This action directly corresponds to the definition of a company buying back its own shares. The relevant filing type is 'Transaction in Own Shares' (POS). The document length is very short (407 chars), but it is a direct announcement of the transaction program itself, not merely an announcement that a report is attached, making POS more specific than RPA or RNS.
2011-05-19 English
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 99% confidence The document text explicitly details transactions made under a share buyback program ('aktietilbagekøbsprogram') conducted between February 11, 2011, and December 31, 2011. It reports the number of shares bought back, the average price, and the total value, concluding with the current holding of treasury shares. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase activities.
2011-05-19 English
Director's Dealing 2011
Director's Dealing Classification · 99% confidence The document explicitly reports transactions made by a company executive ('Thomas Videbæk | EVP, BioBusiness') involving the sale of company shares, including the date, volume, and value of the transaction. This directly aligns with the definition of Director's Dealing (insider trades by executives/directors). The filing category code for this is DIRS.
2011-05-19 English
Director's Dealing 2011
Director's Dealing Classification · 95% confidence The document text is very short (204 characters) and written in Danish. It references the Danish Securities Trading Act ('Værdipapirhandelslovens paragraf 28a') and mentions transactions related to Novozymes shares (Fondskode DK0010272129, NZYM B). This structure strongly suggests a mandatory regulatory disclosure regarding insider transactions or director dealings, as required by local securities law. Given the options, 'Director's Dealing' (DIRS) is the most specific fit for reporting transactions by insiders/directors. Since the text is an announcement snippet and not the full report, and DIRS is a specific category, DIRS is preferred over the general RNS fallback.
2011-05-19 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.